Proteomic and Metabolic Prediction of Response to Therapy in Gastric Cancer

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2014 Oct 17

PMID 25320503

Citations 13

Authors

Michaela Aichler

Birgit Luber

Florian Lordick

Axel Walch

Affiliations

Soon will be listed here.

Abstract

Several new treatment options for gastric cancer have been introduced but the prognosis of patients diagnosed with gastric cancer is still poor. Disease prognosis could be improved for high-risk individuals by implementing earlier screenings. Because many patients are asymptomatic during the early stages of gastric cancer, the diagnosis is often delayed and patients present with unresectable locally advanced or metastatic disease. Cytotoxic treatment has been shown to prolong survival in general, but not all patients are responders. The application of targeted therapies and multimodal treatment has improved prognosis for those with advanced disease. However, these new therapeutic strategies do not uniformly benefit all patients. Predicting whether patients will respond to specific therapies would be of particular value and would allow for stratifying patients for personalized treatment strategies. Metabolic imaging by positron emission tomography was the first technique with the potential to predict the response of esophago-gastric cancer to neoadjuvant therapy. Exploring and validating tissue-based biomarkers are ongoing processes. In this review, we discuss the status of several targeted therapies for gastric cancer, as well as proteomic and metabolic methods for investigating biomarkers for therapy response prediction in gastric cancer.

Citing Articles

Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer.

Jiang Y, Li W, Qiu Y, Yue M World J Gastrointest Oncol. 2024; 16(6):2318-2334.

PMID: 38994153 PMC: 11236256. DOI: 10.4251/wjgo.v16.i6.2318.

Research advances in the molecular classification of gastric cancer.

Shi D, Yang Z, Cai Y, Li H, Lin L, Wu D Cell Oncol (Dordr). 2024; 47(5):1523-1536.

PMID: 38717722 PMC: 11466988. DOI: 10.1007/s13402-024-00951-9.

Exosomal long non-coding RNAs: novel molecules in gastrointestinal cancers' progression and diagnosis.

Roshani M, Baniebrahimi G, Mousavi M, Zare N, Sadeghi R, Salarinia R Front Oncol. 2023; 12:1014949.

PMID: 36591473 PMC: 9795196. DOI: 10.3389/fonc.2022.1014949.

Antigenotoxicity and Cytotoxic Potentials of Cell-Free Supernatants Derived from Saccharomyces cerevisiae var. boulardii on HT-29 Human Colon Cancer Cell Lines.

Abbasi A, Rad A, Maleki L, Kafil H, Baghbanzadeh A Probiotics Antimicrob Proteins. 2023; 15(6):1583-1595.

PMID: 36588138 DOI: 10.1007/s12602-022-10039-1.

LncRNA NEAT1 Promotes the Progression of Gastric Cancer Through Modifying the miR-1224-5p/RSF1 Signaling Axis.

Yang L, Wang M, He P Cancer Manag Res. 2020; 12:11845-11855.

PMID: 33244266 PMC: 7683354. DOI: 10.2147/CMAR.S267666.

References

Herrmann K, Walch A, Balluff B, Tanzer M, Hofler H, Krause B . Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers. Nat Clin Pract Gastroenterol Hepatol. 2009; 6(3):170-83. DOI: 10.1038/ncpgasthep1366. View

Kim H, Reyzer M, Choi I, Kim C, Kim H, Oshima A . Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. J Proteome Res. 2010; 9(8):4123-30. PMC: 3441055. DOI: 10.1021/pr100302b. View

Balluff B, Rauser S, Ebert M, Siveke J, Hofler H, Walch A . Direct molecular tissue analysis by MALDI imaging mass spectrometry in the field of gastrointestinal disease. Gastroenterology. 2012; 143(3):544-549.e2. DOI: 10.1053/j.gastro.2012.07.022. View

Magdeldin S, Yamamoto T . Toward deciphering proteomes of formalin-fixed paraffin-embedded (FFPE) tissues. Proteomics. 2012; 12(7):1045-58. PMC: 3561704. DOI: 10.1002/pmic.201100550. View

Iqbal S, Goldman B, Fenoglio-Preiser C, Lenz H, Zhang W, Danenberg K . Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol. 2011; 22(12):2610-2615. PMC: 3221514. DOI: 10.1093/annonc/mdr021. View

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Mitani Y, Oue N, Matsumura S, Yoshida K, Noguchi T, Ito M . Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. Oncogene. 2007; 26(30):4383-93. DOI: 10.1038/sj.onc.1210215. View

Hecht J, Bang Y, Qin S, Chung H, Xu J, Park J . Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. J Clin Oncol. 2015; 34(5):443-51. DOI: 10.1200/JCO.2015.62.6598. View

Jiang X, Jiang X, Feng S, Tian R, Ye M, Zou H . Development of efficient protein extraction methods for shotgun proteome analysis of formalin-fixed tissues. J Proteome Res. 2007; 6(3):1038-47. DOI: 10.1021/pr0605318. View

10.

de Mello R, Marques A, Araujo A . HER2 therapies and gastric cancer: a step forward. World J Gastroenterol. 2013; 19(37):6165-9. PMC: 3787345. DOI: 10.3748/wjg.v19.i37.6165. View

11.

Ott K, Herrmann K, Lordick F, Wieder H, Weber W, Becker K . Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res. 2008; 14(7):2012-8. DOI: 10.1158/1078-0432.CCR-07-0934. View

12.

Rocken C, Ketterlinus R, Ebert M . Application of proteome analysis to the assessment of prognosis and response prediction in clinical oncology. Curr Cancer Drug Targets. 2008; 8(2):141-5. DOI: 10.2174/156800908783769328. View

13.

Poon T, Sung J, Chow S, Ng E, Yu A, Chu E . Diagnosis of gastric cancer by serum proteomic fingerprinting. Gastroenterology. 2006; 130(6):1858-64. DOI: 10.1053/j.gastro.2006.02.011. View

14.

Ninomiya Y, Yanagisawa A, Kato Y, Kitagawa T, Ishihara S, Nakajima T . Histological indications of a favorable prognosis with far-advanced gastric carcinomas after preoperative chemotherapy. J Cancer Res Clin Oncol. 1999; 125(12):699-706. DOI: 10.1007/s004320050337. View

15.

Huang H, Han Y, Gao J, Feng J, Zhu L, Qu L . High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients. Med Oncol. 2013; 30(4):748. DOI: 10.1007/s12032-013-0748-8. View

16.

Ott K, Herrmann K, Schuster T, Langer R, Becker K, Wieder H . Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol. 2011; 18(12):3316-23. DOI: 10.1245/s10434-011-1743-y. View

17.

Ott K, Fink U, Becker K, Stahl A, Dittler H, Busch R . Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003; 21(24):4604-10. DOI: 10.1200/JCO.2003.06.574. View

18.

Deininger S, Ebert M, Futterer A, Gerhard M, Rocken C . MALDI imaging combined with hierarchical clustering as a new tool for the interpretation of complex human cancers. J Proteome Res. 2009; 7(12):5230-6. DOI: 10.1021/pr8005777. View

19.

Xia Q, Kong X, Zhang G, Hou X, Qiang H, Zhong R . Proteomics-based identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer. Biochem Biophys Res Commun. 2005; 330(2):526-32. DOI: 10.1016/j.bbrc.2005.02.181. View

20.

Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T . Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med. 2003; 44(5):690-9. View